- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT00274716
Safety and Efficacy of MK0736 & MK0916 in Patients With Hypertension (High Blood Pressure)(0736-003)(COMPLETED)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of MK0736 and MK0916 in Hypertensive Patients
The objective of this study is to evaluate the safety and efficacy of two investigational drugs (MK-0736 and MK-0916) in lowering blood pressure and body weight in patients with hypertension (high blood pressure).
This is an early phase trial and some specific protocol information is proprietary and not publicly available at this time. (Full information is available to trial participants).
Обзор исследования
Статус
Условия
Вмешательство/лечение
Подробное описание
Тип исследования
Регистрация (Действительный)
Фаза
- Фаза 2
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Hypertension systolic blood pressure (SBP) </= 160mm Hg and diastolic blood pressure (DBP): 90-105mm Hg
Exclusion Criteria:
- Pre-menopausal women
- patients currently taking more than two (2) blood pressure lowering medications
- Body Mas Index (BMI)>40 kg/m2 (morbidly obese patients)
- History of Alcohol abuse (<3 Years)
- History of diabetes,chronic kidney disease, Active liver disease, recent heart attack or stroke
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Двойной
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
---|---|
Экспериментальный: High BMI:MK-0736 2mg→Placebo
Participants administered MK-0736 2mg tablet once daily for 12 weeks (Phase A) then administered placebo once daily for 12 weeks (Phase B)
|
|
Экспериментальный: High BMI:MK-0736 7mg→Placebo
Participants administered MK-0736 7mg tablet once daily for 12 weeks (Phase A) then administered placebo once daily for 12 weeks (Phase B)
|
|
Экспериментальный: High BMI:MK-0916 6mg→MK-0916 6mg
Participants administered MK-0916 6mg tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)
|
|
Плацебо Компаратор: High BMI:Placebo→Placebo
Participants administered placebo tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)
|
|
Экспериментальный: Low BMI:MK-0916 6mg→MK-0916 6mg
Participants administered MK-0916 6mg tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)
|
|
Плацебо Компаратор: Low BMI:Placebo→Placebo
Participants administered placebo tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
---|---|---|
Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12 in Participants With Higher Body Mass Indices (BMI)
Временное ограничение: Baseline and Week 12 (end of Phase A)
|
Sitting diastolic blood pressure measured in triplicate at baseline and after 12 weeks of study drug administration.
Mean value of the 3 measurements at the 2 timepoints was recorded.
|
Baseline and Week 12 (end of Phase A)
|
Number of Participants Who Reported a Clinical Adverse Event
Временное ограничение: 24 weeks
|
An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product.
Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the SPONSOR'S product, is also an AE.
A clinical AE was an AE reported as a result of a clinical examination.
|
24 weeks
|
Number of Participants Who Reported a Laboratory Adverse Event
Временное ограничение: 24 weeks
|
An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product.
Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the SPONSOR'S product, is also an AE.
A laboratory AE was an AE reported as a result of a laboratory assessment or test.
|
24 weeks
|
Number of Participants Who Were Discontinued From Study Due to Clinical Adverse Event
Временное ограничение: 24 weeks
|
An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product.
Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the SPONSOR'S product, is also an AE.
A clinical AE was an AE reported as a result of a clinical examination.
|
24 weeks
|
Number of Participants Who Were Discontinued From Study Due to Laboratory Adverse Event
Временное ограничение: 24 weeks
|
An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product.
Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the SPONSOR'S product, is also an AE.
A laboratory AE was an AE reported as a result of a laboratory assessment or test.
|
24 weeks
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
---|---|---|
Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP) at Week 12 in Participants With Higher Body Mass Indices (BMI)
Временное ограничение: Baseline and Week 12 (end of Phase A)
|
Sitting systolic blood pressure measured in triplicate at baseline and after 12 weeks of study drug administration.
Mean trough value of the 3 measurements at the 2 timepoints was recorded.
|
Baseline and Week 12 (end of Phase A)
|
Change From Baseline in Body Weight (kg) at Week 12 in Participants With Higher BMI
Временное ограничение: Baseline and Week 12 (end of Phase A)
|
Weight was measured in duplicate (2 measurements) at baseline and after 12 weeks of study drug administration.
The mean of the 2 values at each assessment was used in analysis.
|
Baseline and Week 12 (end of Phase A)
|
Change From Baseline in Waist Circumference at Week 12 in Participants With Higher BMI
Временное ограничение: Baseline and Week 12 (end of Phase A)
|
Waist circumference measured in cm at baseline and after 12 weeks of study drug administration
|
Baseline and Week 12 (end of Phase A)
|
Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12 in Participants With Higher Body Mass Indices (BMI)
Временное ограничение: Baseline and Week 12 (end of Phase A)
|
LDL-C was calculated by the method of Friedewald equation at baseline and after 12 weeks of study drug administration.
|
Baseline and Week 12 (end of Phase A)
|
Change From Baseline for High Density Lipoprotein Cholesterol (HDL-C) at Week 12 in Participants With Higher BMI
Временное ограничение: Baseline and Week 12 (end of Phase A)
|
HDL-C measured at baseline and after 12 weeks of study drug administration.
|
Baseline and Week 12 (end of Phase A)
|
Percent Change From Baseline in Triglycerides (TG) at Week 12 in Participants With Higher Body Mass Indices (BMI)
Временное ограничение: Baseline and Week 12 (end of Phase A)
|
TG measured at baseline and after 12 weeks of study drug administration
|
Baseline and Week 12 (end of Phase A)
|
Соавторы и исследователи
Спонсор
Публикации и полезные ссылки
Даты записи исследования
Изучение основных дат
Начало исследования
Первичное завершение (Действительный)
Завершение исследования (Действительный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Оценивать)
Обновления учебных записей
Последнее опубликованное обновление (Оценивать)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- 0736-003
- 2006_004
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .
Клинические исследования Плацебо
-
University of FloridaЗавершенныйАпноэ сна, обструктивное | ХрапСоединенные Штаты
-
Centre Hospitalier Universitaire de Saint EtienneЗавершенный
-
PfizerЗавершенныйАтопический дерматитКитай, Япония, Корея, Республика
-
Tasly Pharmaceutical Group Co., LtdНеизвестныйСиндром раздраженного кишечника с диареейКитай
-
Guang'anmen Hospital of China Academy of Chinese...НеизвестныйИшемическая болезнь сердца | Нестабильная стенокардия | Синдром застоя кровиКитай
-
University Hospital, Clermont-FerrandРекрутингОральный мукозитФранция
-
Henan University of Traditional Chinese MedicineJiangsu Province Hospital of Traditional Chinese MedicineНеизвестныйХроническое обструктивное заболевание легкихКитай
-
Universidad Francisco de VitoriaЗавершенныйПищевая добавка | Спортивная производительностьИспания
-
TakedaЗавершенныйХроническая бессонницаСоединенные Штаты
-
TakedaЗавершенныйХроническая бессонница